RightCare Solutions, Inc. Assesses 30,000th Patient for Risk of Readmission
July 17, 2013RightCare Solutions, Inc. Assesses 30,000th Patient for Risk of Readmission
More »
FDA Grants Fast Track Designation to Adynxx Lead Compound AYX1
July 17, 2013Adynxx is developing a first-in-class therapeutic platform to address pain at its molecular roots. AYX1 Injection has Fast Track designation for the prevention of chronic pain and is in Phase 2 to study post-surgical pain reduction or prevention.
More »
Ocera Therapeutics Announces Completion of Merger With Tranzyme
July 15, 2013The combined company will be named Ocera Therapeutics (NASDAQ: OCRX) and will continue the development of OCR-002, which is currently in Phase 2 clinical trial to treat hepatic encephalopathy in patients with decompensated liver cirrhosis.
More »